Dimethyl fumarate for multiple sclerosis

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the absolute and comparative efficacy and safety of dimethyl fumarate as monotherapy or combination therapy versus placebo or other approved disease-modifying drugs (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab) for patients with MS.